Profund Advisors’s Kailera Therapeutics KLRA Stock Holding History

Profund Advisors’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$216K	Buy	+18,880	New	+$319K	0.01%	949

Other funds holding KLRA

Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Profund Advisors's KLRA Position: Q3 2026 in Review

Profund Advisors opened a new position in Kailera Therapeutics (KLRA) in Q3 2026: 18,880 shares worth $216K. The stake represents 0.01% of the portfolio and ranks #949 among its holdings.

14 funds tracked by Wall St. Rank hold KLRA as of Q3 2026.

Profund Advisors held 18,880 shares of Kailera Therapeutics worth $216K as of Q3 2026.
Kailera Therapeutics was a new Profund Advisors position in Q3 2026.
Kailera Therapeutics made up 0.01% of Profund Advisors's portfolio in Q3 2026, its #949 holding.
14 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.